Less fluid means lower pressure
GLP-1 receptor agonists Including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are peptide-based drugs that have completed full FDA review and carry approved indications for type 2 diabetes and obesity
These supplements also appeal to those following specific dietary patterns
Additionally, semaglutide treatment protected synaptic plasticity and reversed the hippocampal neuroinflammation induced by HFD fed, improving activation of the insulin pathway, demonstrating the protective effects of semaglutide
College and university benefits teams are not exempt from these challenges, and some are implementing robust prior authorization and utilization management to help contend with rising costs, while still offering coverage options
This matters because GLP-1 therapy involves metabolic, cardiovascular, and gastrointestinal considerations that deserve thorough screening